Drug
Ly4268989
Ly4268989: highest development phase Phase 2, developed by Eli Lilly. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| LY4268989 NCT07415044 | Phase 2 | Ulcerative Colitis (UC) |
| LY4268989 NCT07186101 | Phase 2 | Ulcerative Colitis |
Latest
No recent events.
Follow Ly4268989 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.